Core Viewpoint - PPL Corporation has announced the pricing of its public offering of 20,000,000 Equity Units, aiming to raise approximately $1 billion to repay short-term debt and for general corporate purposes [1]. Group 1: Offering Details - Each Equity Unit is priced at $50, leading to an aggregate stated amount of $1,000,000,000 [1]. - The offering includes a Corporate Unit that consists of a contract to purchase PPL common stock, along with beneficial ownership interests in two sets of Remarketable Senior Notes due in 2034 and 2039, each with a principal amount of $1,000 [1]. - Total distributions on the Corporate Units will be at a rate of 7.00% per year, which includes interest payments on the Remarketable Senior Notes and contract adjustment payments [1]. Group 2: Purchase Contracts - Holders of the purchase contracts are required to buy a variable number of shares of PPL common stock by February 15, 2029, with a reference price of $37.2606 per share [1]. - The minimum settlement rate is 1.0735 shares per Equity Unit, while the maximum settlement rate is 1.3419 shares per Equity Unit, both subject to adjustments [1]. Group 3: Financial Proceeds and Use - The net proceeds from the offering are expected to be approximately $981 million, or $1,128 million if the over-allotment option is fully exercised [1]. - The proceeds will primarily be used to repay short-term debt and for general corporate purposes [1]. Group 4: Underwriters and Listing - J.P. Morgan Securities LLC, BofA Securities, Morgan Stanley & Co. LLC, and RBC Capital Markets, LLC are the joint book-running managers for the offering [1]. - PPL Corporation intends to list the Corporate Units on The New York Stock Exchange, with trading expected to commence within 30 days of the initial issuance [1].

Core Viewpoint - Frontera Energy Corporation acknowledges receipt of an unsolicited acquisition proposal from Parex Resources for its Colombian upstream exploration and production assets, which are also under an agreement to be sold to GeoPark Limited [1] Group 1: Acquisition Proposals - Frontera has received an unsolicited proposal from Parex Resources to acquire its upstream Colombian exploration and production business [1] - The assets in question are the same that Frontera has agreed to sell to GeoPark Limited under a previously announced arrangement agreement dated January 29, 2026 [1] - The Frontera Board of Directors is reviewing the Parex proposal while continuing to recommend the GeoPark transaction to its shareholders [1] Group 2: Company Overview - Frontera Energy Corporation is a Canadian public company engaged in the exploration, development, production, transportation, storage, and sale of oil and natural gas in South America [1] - The company has a diversified portfolio with interests in 18 exploration and production blocks in Colombia and Guyana, along with pipeline and port facilities in Colombia [1] - Frontera is committed to conducting its business in a socially, environmentally, and ethically responsible manner [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and disclosures [1]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by April 21, 2026, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. Group 3: Case Specifics - The lawsuit claims that Corcept misrepresented the strength of clinical trials for relacorilant, suggesting it was a strong candidate for FDA approval, while the FDA had raised concerns about the clinical evidence [5]. - The defendants allegedly assured investors that there were no impediments to the New Drug Application (NDA) approval, which was later contradicted by the FDA's concerns [5]. - When the true situation regarding the NDA was revealed, investors reportedly suffered damages [5].

Core Viewpoint - CNX Resources Corporation has successfully completed a cash tender offer for its 6.000% Senior Notes due 2029, with 84.04% of the notes tendered, and plans to redeem the remaining notes contingent on a new senior notes offering [1] Group 1: Tender Offer Details - The total principal amount of the 2029 Notes outstanding is $500 million, with tenders received for $420,200,000 [1] - The purchase price for the validly tendered 2029 Notes is set at $1,016.10 for each $1,000 principal amount, plus accrued interest [1] - The settlement date for the tender offer is scheduled for February 26, 2026, after which interest will cease to accrue on the accepted notes [1] Group 2: Redemption Conditions - CNX has issued a conditional notice to redeem all 2029 Notes not purchased in the tender offer at a redemption price of 101.50% of the principal amount, plus accrued interest [1] - The redemption is contingent upon the successful closing of a new senior notes offering and receipt of net proceeds [1] - There is no assurance that the redemption will be completed, as it may be terminated if conditions are not met by the redemption date of March 19, 2026 [1] Group 3: Company Overview - CNX Resources Corporation is a leading natural gas development and production company based in Appalachia, with a focus on ultra-low carbon intensity [1] - As of December 31, 2025, the company reported 9.7 trillion cubic feet equivalent of proved natural gas reserves [1] - CNX is a member of the Standard & Poor's Midcap 400 Index, highlighting its significant market presence [1]

Core Viewpoint - G2M Cap Corp. is proceeding with a special shareholder meeting to approve its acquisition of SalesCloser AI from Wishpond Technologies, alongside an upsized concurrent financing due to strong investor interest [1] Group 1: Special Shareholder Meeting - The special shareholder meeting will take place on March 20, 2026, at 9:30 a.m. PST in Vancouver, BC, to discuss the qualifying transaction involving G2M's acquisition of SalesCloser [1] - Details regarding the meeting and transaction can be found in G2M's information circular filed on SEDAR+ [1] Group 2: Concurrent Financing - The concurrent financing has been increased from $4,000,000 to $5,000,000, with an option to further increase by $500,000, totaling up to $5,500,000 [1] - Each subscription receipt will be priced at $0.75 and will convert into one unit of the resulting issuer, which includes one common share and one half of a warrant [1] - The warrants will be exercisable at $1.25 per share for 24 months post-closing, with provisions for acceleration if the share price exceeds $1.80 for ten consecutive trading days [1]

Core Viewpoint - Union Electric Company, operating as Ameren Missouri, has announced a public offering of $450 million in first mortgage bonds with two different maturities, indicating a strategic move to raise capital for future investments [1] Group 1: Bond Offering Details - The company is offering $450 million aggregate principal amount of 4.80% first mortgage bonds due in 2036, priced at 99.926% of their principal amount [1] - Additionally, the company is offering $450 million aggregate principal amount of 5.55% first mortgage bonds due in 2056, priced at 99.619% of their principal amount [1] - The transaction is expected to close on February 27, 2026, pending customary closing conditions [1]

Core Insights - Tyra Biosciences, Inc. announced the acceptance of two abstracts for presentation at the 2026 ASCO Genitourinary Cancers Symposium, highlighting its focus on FGFR biology and precision medicine development [1] Group 1: Presentation Details - The first presentation is titled "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial," scheduled for February 27, 2026, from 11:30 AM to 12:45 PM PST [1] - The second presentation is a phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302), also on February 27, 2026, from 11:30 AM to 12:45 PM PST [1] Group 2: Company Overview - Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology, with a proprietary platform called SNÃ…P for rapid drug design [1] - The company has a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions, including oral dabogratinib, a potential first-in-class selective FGFR3 inhibitor [1] - Current planned clinical development includes three Phase 2 studies: SURF303 for low-grade upper tract urothelial carcinoma, SURF302 for intermediate risk non-muscle invasive bladder cancer, and BEACH301 for pediatric achondroplasia [1]

Core Viewpoint - Haivision Systems Inc. is set to announce its financial results for the first quarter of fiscal 2026 on March 12, 2026, after market close, with a conference call scheduled for March 13, 2026, to discuss these results [1]. Company Overview - Haivision is a leading global provider of mission-critical, real-time video networking and visual collaboration solutions, headquartered in Montreal and Chicago, with a presence across the Americas, Europe, and Asia [1]. - The company specializes in high-quality, low-latency, secure, and reliable live video solutions, leveraging connected cloud and intelligent edge technologies to enhance collaboration and decision-making [1]. - Haivision is recognized for its contributions to the industry, having open-sourced its SRT low latency video streaming protocol and founded the SRT Alliance to promote its adoption [1]. - The company has received an Emmy® award for Technology and Engineering from the National Academy of Television Arts and Sciences, underscoring its role in the transformation of IP video [1].

Other17.4420.8818.9419.70Total NGLs32.7635.3436.0335.28Natural GasNYMEX ($/MMBtu)3.552.793.432.27Realized Natural Gas Price ($/Mcf)2.652.422.542.17Cost Summary(for the period ended December 31)($/BOE)20252024Production, mineral and other taxes1.271.56Upstream transportation and processing7.517.25Upstream operating3.804.24Administrative, excluding long-term incentive, restructuring, transaction and legal costs1.261.32Debt to EBITDA (1)($ millions, except as indicated)December 31, 2025December 31, 2024Long-Te ...

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO- XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer [Accessibility Statement] Skip Navigation--Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)Vir Biotechnology- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of e ...